Detalhe da pesquisa
1.
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Blood
; 115(15): 3109-17, 2010 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20130243
2.
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
J Immunol
; 184(9): 5298-307, 2010 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20363976
3.
Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream.
Pharmaceutics
; 13(7)2021 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34371735
4.
Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans.
Drug Metab Dispos
; 38(11): 2023-31, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20699411
5.
Metathesis approach to the synthesis of polyheterocyclic structures from oxanorbornenes.
Org Lett
; 6(21): 3821-4, 2004 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-15469358
6.
Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
J Invest Dermatol
; 131(9): 1838-44, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21677670
7.
Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction.
Org Lett
; 11(9): 1999-2002, 2009 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-19385672